参考文献:
[1]中华医学会血液学分会白血病淋巴瘤学组,中华医学会病理学分会,BCR::ABL1阴性骨髓增殖性肿瘤病理诊断中国专家共识(2023版)专家编写组. BCR::ABL1阴性骨髓增殖性肿瘤病理诊断中国专家共识(2023版)[J].中华病理学杂志,2023,52(09):891-901.DOI:10.3760/cma.j.cn112151-20230609-00383[2]arbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms:document summary and in-depth discussion[J]. Blood Cancer J,2018, 8(2): 15. DOI: 10.1038/s41408-018-0054-y[3] Boddu P, Masarova L, Verstovsek S, et al. Patient characteristicsand outcomes in adolescents and young adults with classicalPhiladelphia chromosome- negative myeloproliferative neoplasms[J]. Ann Hematol, 2018, 97(1): 109-121. DOI: 10.1007/s00277-017-3165-9.[4]张梦雨,宝梅,石红霞,等. 中国年轻骨髓增殖性肿瘤患者的临床和基因突变特征[J]. 中华血液学杂志,2023,44(03):193-201.DOI:10.3760/cma.j.issn.0253-2727.2023.03.004